{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:27:05Z","timestamp":1790616425689,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s12325-016-0434-2","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T05:11:01Z","timestamp":1479359461000},"page":"41-59","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview"],"prefix":"10.1007","volume":"34","author":[{"given":"Jaime A.","family":"Davidson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,16]]},"reference":[{"key":"434_CR1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4158\/EP151126.CS","volume":"22","author":"AJ Garber","year":"2016","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142016 executive summary. Endocr Pract. 2016;22:84\u2013113.","journal-title":"Endocr Pract"},{"key":"434_CR2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140\u20139.","journal-title":"Diabetes Care"},{"key":"434_CR3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc16-er09","volume":"39","author":"American Diabetes Association","year":"2016","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142016. Diabetes Care. 2016;39:S1\u2013108.","journal-title":"Diabetes Care"},{"key":"434_CR4","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMcibr1409796","volume":"371","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E. The target of metformin in type 2 diabetes. N Engl J Med. 2014;371:1547\u20138.","journal-title":"N Engl J Med"},{"key":"434_CR5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2337\/dc16-1340","volume":"39","author":"JB Buse","year":"2016","unstructured":"Buse JB, Defronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016;39:198\u2013205.","journal-title":"Diabetes Care"},{"key":"434_CR6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2337\/diacare.24.3.489","volume":"24","author":"E Mannucci","year":"2001","unstructured":"Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001;24:489\u201394.","journal-title":"Diabetes Care"},{"key":"434_CR7","doi-asserted-by":"crossref","first-page":"e100778","DOI":"10.1371\/journal.pone.0100778","volume":"9","author":"A Napolitano","year":"2014","unstructured":"Napolitano A, Miller S, Nicholls AW, et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 2014;9:e100778.","journal-title":"PLoS One"},{"key":"434_CR8","unstructured":"GLUCOPHAGE\/GLUCOPHAGE\u00ae XR (metformin hydrochloride) extended-release tablets [package insert]. Princeton: Bristol-Myers Squibb Company; 2015."},{"key":"434_CR9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3810\/pgm.2011.01.2241","volume":"123","author":"S Jabbour","year":"2011","unstructured":"Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad Med. 2011;123:15\u201323.","journal-title":"Postgrad Med"},{"key":"434_CR10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1464-5491.2007.02078.x","volume":"24","author":"MN Cook","year":"2007","unstructured":"Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabet Med. 2007;24:350\u20138.","journal-title":"Diabet Med"},{"key":"434_CR11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2337\/diacare.28.5.995","volume":"28","author":"MN Cook","year":"2005","unstructured":"Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care. 2005;28:995\u20131000.","journal-title":"Diabetes Care"},{"key":"434_CR12","unstructured":"Texas Diabetes Council. Glycemic control algorithm for type 2 diabetes mellitus in adults. 2015. http:\/\/www.tdctoolkit.org\/algorithms-guidelines\/ . Accessed 11 Aug 2016."},{"key":"434_CR13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","volume":"9","author":"EC Chao","year":"2010","unstructured":"Chao EC, Henry RR. SGLT2 inhibition\u2014a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9:551\u20139.","journal-title":"Nat Rev Drug Discov"},{"key":"434_CR14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/nyas.12852","volume":"1358","author":"N Rosenthal","year":"2015","unstructured":"Rosenthal N, Meininger G, Ways K, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci. 2015;1358:28\u201343.","journal-title":"Ann N Y Acad Sci"},{"key":"434_CR15","unstructured":"INVOKAMET\u00ae (canagliflozin and metformin hydrochloride) tablets for oral use [package insert]. Titusville: Janssen Pharmaceuticals, Inc; 2016."},{"key":"434_CR16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/dc15-1736","volume":"39","author":"J Rosenstock","year":"2016","unstructured":"Rosenstock J, Chuck L, Gonz\u00e1lez-Ortiz M, Merton K, Craig J, Capuano G. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy in drug-na\u00efve type 2 diabetes. Diabetes Care. 2016;39:353\u201362.","journal-title":"Diabetes Care"},{"key":"434_CR17","unstructured":"INVOKAMET\u00ae XR (canagliflozin and metformin hydrochloride extended-release) tablets, for oral use. Titusville: Janssen Pharmaceuticals; 2016."},{"key":"434_CR18","first-page":"164","volume":"6","author":"D Devineni","year":"2014","unstructured":"Devineni D, Curtin CR, Ariyawansa J, et al. Bioequivalence of canagliflozin\/metformin immediate release fixed-dose combination tablets compared with concomitant administration of single components of canagliflozin and metformin in healthy fed participants. J Bioequiv Avail. 2014;6:164\u201373.","journal-title":"J Bioequiv Avail"},{"key":"434_CR19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5414\/CP202233","volume":"53","author":"J Murphy","year":"2015","unstructured":"Murphy J, Wang SS, Stieltjes H, Wajs E, Devineni D. Effect of food on the pharmacokinetics of canagliflozin\/metformin (150\/1,000\u00a0mg) immediate-release fixed-dose combination tablet in healthy participants. Int J Clin Pharmacol Ther. 2015;53:256\u201364.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"434_CR20","unstructured":"INVOKANA\u00ae (canagliflozin) tablets, for oral use [package insert]. Titusville: Janssen Pharmaceuticals; 2016."},{"key":"434_CR21","doi-asserted-by":"crossref","first-page":"438","DOI":"10.5414\/CP202324","volume":"53","author":"D Devineni","year":"2015","unstructured":"Devineni D, Polidori D, Curtin CR, et al. Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. Int J Clin Pharmacol Ther. 2015;53:438\u201346.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"434_CR22","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","volume":"35","author":"J Rosenstock","year":"2012","unstructured":"Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232\u20138.","journal-title":"Diabetes Care"},{"key":"434_CR23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcte.2014.04.001","volume":"1","author":"R Qiu","year":"2014","unstructured":"Qiu R, Capuano G, Meininger G. Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus. J Clin Transl Endocrinol. 2014;1:54\u201360.","journal-title":"J Clin Transl Endocrinol"},{"key":"434_CR24","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"FJ Lavalle-Gonz\u00e1lez","year":"2013","unstructured":"Lavalle-Gonz\u00e1lez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582\u201392.","journal-title":"Diabetologia"},{"key":"434_CR25","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52\u00a0week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941\u201350.","journal-title":"Lancet"},{"key":"434_CR26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.12273","volume":"16","author":"T Forst","year":"2014","unstructured":"Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52\u00a0weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16:467\u201377.","journal-title":"Diabetes Obes Metab"},{"key":"434_CR27","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","volume":"67","author":"JP Wilding","year":"2013","unstructured":"Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67:1267\u201382.","journal-title":"Int J Clin Pract"},{"key":"434_CR28","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","volume":"36","author":"G Schernthaner","year":"2013","unstructured":"Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care. 2013;36:2508\u201315.","journal-title":"Diabetes Care"},{"key":"434_CR29","unstructured":"Rosenstock J, Matthews DR, Desai M, Capuano G, Meininger G, Canovatchel W. Impact of canagliflozin added-on to insulin and metformin in type 2 diabetes: a substudy of the CANVAS trial. Poster presented at the 75th Scientific Sessions of the American Diabetes Association (ADA); June 5\u20139, 2015; Boston, Massachusetts."},{"key":"434_CR30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2337\/dc13-2762","volume":"38","author":"LA Leiter","year":"2015","unstructured":"Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104\u00a0weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38:355\u201364.","journal-title":"Diabetes Care"},{"key":"434_CR31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2014.05.2753","volume":"126","author":"K Usiskin","year":"2014","unstructured":"Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes: pooled analysis of phase 3 study results. Postgrad Med. 2014;126:16\u201334.","journal-title":"Postgrad Med"},{"key":"434_CR32","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2337\/dc15-1251","volume":"38","author":"N Erondu","year":"2015","unstructured":"Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38:1680\u20136.","journal-title":"Diabetes Care"},{"key":"434_CR33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","volume":"101","author":"NB Watts","year":"2016","unstructured":"Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101:157\u201366.","journal-title":"J Clin Endocrinol Metab"},{"key":"434_CR34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/dom.12015","volume":"15","author":"DS Bell","year":"2013","unstructured":"Bell DS. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab. 2013;15:291\u2013300.","journal-title":"Diabetes Obes Metab"},{"key":"434_CR35","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1185\/03007995.2011.570745","volume":"27","author":"V Hutchins","year":"2011","unstructured":"Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27:1157\u201368.","journal-title":"Curr Med Res Opin"},{"key":"434_CR36","first-page":"40","volume":"21","author":"SA Williams","year":"2012","unstructured":"Williams SA, Buysman EK, Hulbert EM, Bergeson JG, Zhang B, Graham J. Hemoglobin A1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations. Manag Care. 2012;21:40\u20138.","journal-title":"Manag Care"},{"key":"434_CR37","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.clinthera.2008.10.003","volume":"30","author":"C Cheong","year":"2008","unstructured":"Cheong C, Barner JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther. 2008;30:1893\u2013907.","journal-title":"Clin Ther"},{"key":"434_CR38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/14746514080080010901","volume":"8","author":"J Ray","year":"2008","unstructured":"Ray J, Huet D, Valentine W, Palmer A, Cugnardey N, Renaudin C. Long-term costs and clinical outcomes associated with metformin-glibenclamide combination tablets (Glucovance\u00ae) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting. Br J Diabetes Vasc Dis. 2008;8:39\u201344.","journal-title":"Br J Diabetes Vasc Dis"},{"key":"434_CR39","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/PPA.S33968","volume":"6","author":"G Colombo","year":"2012","unstructured":"Colombo G, Rossi E, De Rosa M, Benedetto D, Gaddi A. Antidiabetic therapy in real practice: indicators for adherence and treatment cost. Patient Prefer Adher. 2012;6:653\u201361.","journal-title":"Patient Prefer Adher"},{"key":"434_CR40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12325-013-0001-z","volume":"30","author":"S Genovese","year":"2013","unstructured":"Genovese S, Tedeschi D. Effects of vildagliptin\/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization. Adv Ther. 2013;30:152\u201364.","journal-title":"Adv Ther"},{"key":"434_CR41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","volume":"15","author":"JF Yale","year":"2013","unstructured":"Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463\u201373.","journal-title":"Diabetes Obes Metab"},{"key":"434_CR42","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","volume":"16","author":"JF Yale","year":"2014","unstructured":"Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52\u00a0weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16:1016\u201327.","journal-title":"Diabetes Obes Metab"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0434-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T03:47:43Z","timestamp":1498362463000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0434-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,16]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["434"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0434-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,16]]}}}